Transforming the DMTA Cycle Through Enhanced Collaboration

In the rapidly evolving field of drug discovery, the need for streamlined processes and collaboration across the entire design-make-test-analyze (DMTA) cycle has never been more critical. Does technology hold the potential to solve some of the most pressing challenges, such as changing working patterns and the need for efficient teamwork and open communication?

In our recent thought leadership webinar with FierceBiotech, we explored the transformational role that technology can play within the changing working landscape of drug discovery. The webinar was chaired by Rob Scoffin, our CEO, who initially summarized his thoughts on the mindset shift that drug discovery, thanks in part to technological advances, has recently seen.

Rob’s thoughts were echoed by his accompanying panel of guest speakers, each of whom joined to share their own unique insights, stemming from their extensive and diverse career pathways within the drug discovery space.

With thanks to our guest speakers (left to right): Steve Djuric, President at Discovery Chemistry and Technology Consulting LLC; Sabine Ruppel, VP, Discovery Research at Ikena Oncology; Lewis Vidler, Senior Director – Structure-Based Drug Design at Eli Lilly; and Lewis (Lou) Whitehead, Vice President of Research at Acelot.

Watch the below webinar recording to listen to the insightful panel discussions, centered around three main discussion points:

• Drug discovery: what has changed in recent years, and what longer-term trends have been accelerated by the COVID-19 pandemic?
• How can technology help to address these challenges by improving collaboration?
• Artificial Intelligence (AI) and Machine Learning (ML) – from hype to being used in practice

Explore how Cresset solutions can enhance collaboration across your teams - request an evaluation, demo, or discussion, and transform your DMTA cycle.